SecBot SecBot
SECBOTREPLAY Home › Report › DRTS

DRTS · Alpha Tau Medical reported its 2025 financial results, showing a wider…

Alpha Tau Medical Ltd. · PRESS-RELEASE filed Mar 9, 2026 at 16:02 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Mar 9, 2026 at 16:02 ET

Alpha Tau Medical reported its 2025 financial results, showing a wider net loss of $42.6 million ($0.53/share) compared to $31.8 million ($0.45/share) in 2024, driven by higher R&D and G&A expenses. Despite the increased loss, the company highlighted significant clinical and regulatory progress, including Japanese marketing approval for head and neck cancer, five U.S. trial approvals, and positive pancreatic cancer data presented at ASCO GI, while ending the year with $76.9 million in cash.

  • Net loss widened to $42.6M in 2025 from $31.8M in 2024
  • R&D expenses increased to $32.1M from $27.0M in 2024
  • Cash, cash equivalents, and deposits totaled $76.9M as of Dec 31, 2025
  • Received marketing approval in Japan for head and neck cancer

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access